Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

A Case of Malignant Melanoma During Hormone Therapy

폐경기 호르몬 치료 중 발생한 악성 흑색종 1례

  • Sung, Jung-Yeob (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Kim, Hoon (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Kim, Yong-Jin (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Ku, Seung-Yup (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Kim, Seok-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Choi, Young-Min (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Kim, Jung-Gu (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) ;
  • Moon, Shin-Yong (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
  • 성중엽 (서울대학교 의과대학 산부인과학교실) ;
  • 김훈 (서울대학교 의과대학 산부인과학교실) ;
  • 김용진 (서울대학교 의과대학 산부인과학교실) ;
  • 구승엽 (서울대학교 의과대학 산부인과학교실) ;
  • 김석현 (서울대학교 의과대학 산부인과학교실) ;
  • 최영민 (서울대학교 의과대학 산부인과학교실) ;
  • 김정구 (서울대학교 의과대학 산부인과학교실) ;
  • 문신용 (서울대학교 의과대학 산부인과학교실)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Over the last several decades, the incidence of malignant melanoma has been increasing rapidly. The annual incidence rates have increased approximately 3~7% in Caucasian population. The rate of increase is highest in perimenopausal period in women. The relationship between risk of melanoma and female hormone is still unclear. The safety of hormone therapy for the melanoma patients is not known. We experienced a case of melanoma in whom underwent hormone therapy for 10 years. We report this case with a brief review of literature.

악성 흑색종의 유병률은 계속 증가하고 있는데, 미국 및 유럽의 역학조사에 따르면, 그 증가율은 매년 3~7% 정도로 보고되고 있다. 여성에서 악성 흑색종의 유병률은 호르몬 치료를 시작하는 폐경전후기에 그 증가율이 가장 높다. 악성 흑색종과 여성 호르몬사이의 관련성에 관한 여러 연구가 있었으나, 아직 그 관계는 불명확한 상태이다. 또한 흑색종 환자에 대한 호르몬 치료의 안전성 역시 입증되지 않은 상태이다. 저자들은 55세부터 지속적 황체호르몬 병합 요법을 통한 에스트로겐 보충요법 및 티볼론 제제로 호르몬 치료를 받은 65세 여성에서 발생한 악성 흑색종 1례를 경험하여, 이를 문헌고찰과 함께 보고하는 바이다.

Keywords

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. A cancer journal for clinicians 2008; 58: 71-96 https://doi.org/10.3322/CA.2007.0010
  2. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25: 459-63 https://doi.org/10.1046/j.1365-2230.2000.00693.x
  3. Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002; 84: 67-74 https://doi.org/10.1016/S0300-9084(01)01360-8
  4. Nicholas K. Genetics of melanoma predisposition. Oncogene 2003; 22: 3053-62 https://doi.org/10.1038/sj.onc.1206445
  5. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988; 42: 821-4 https://doi.org/10.1002/ijc.2910420603
  6. Boyle P, Robertson C. Age-period-cohort modeling of malignant melanoma in Scotland : epidemiologic implications. Am J Epidemiol 1987; 125: 766
  7. Snell RS, Bischitz PG. The effect of large doses of estrogen and progesterone on melanin pigmentation. J invest Dermatol 1960; 35: 73-82
  8. Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet 1976; 2: 337-9
  9. Chaudhuri PK, Walker MJ, Briele HA, Beattie CW, Gupta TK. Incidence of estrogen receptors in benign nevi and human malignant melanoma. JAMA 1980; 244: 791-3 https://doi.org/10.1001/jama.244.8.791
  10. Miller JG, Gee J, Price A, Garbe C, Wagner M, Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res 1997; 7: 197-208 https://doi.org/10.1097/00008390-199706000-00003
  11. Sanchez NP, Pathak M, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Mc jr. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698-710 https://doi.org/10.1016/S0190-9622(81)70071-9
  12. Bertrand G. Melanotic adenocarcinoma of the uterus. Neuroendocrine tumor of the uterus. Ann pathol 1988; 9: 295-304 https://doi.org/10.1016/j.anndiagpath.2005.05.005
  13. Palmer HR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warchauer ME, et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3: 547-54 https://doi.org/10.1007/BF00052752
  14. Feskanich D, Hunter DJ, Willett WC, Spiegelman D, Stampfer MJ, Speizer FE, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81: 918-23 https://doi.org/10.1038/sj.bjc.6690787
  15. Lea CS, Holly EA, Hartge P, Lee JS, Guerry D 4th, Elder DE, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007; 165: 505-13
  16. Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86: 1085-92 https://doi.org/10.1038/sj.bjc.6600196
  17. Mackie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J cancer 2004; 90: 770-2 https://doi.org/10.1038/sj.bjc.6601595
  18. Kalogirou D, Aroni K, Kalogirou O, Antoniou G, Botsis D, Kontoravdis A. Histological changes induced by tibolone and estrogen/glucocorticoid on aging skin. Int J Fertil Womens Med. 2000; 45: 273-8
  19. Durvasula R, Ahmed SM, Vashisht A, Studd JW. Hormone replacement therapy and malignant melanoma: to prescribe or not to prescribe? Climacteric 2002; 5: 197-200